Tryptamine Therapeutics (ASX:TYP) EV-to-Revenue : 18.53 (As of May. 27, 2024)

Tryptamine Therapeutics EV-to-Revenue Chart

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial						-	193.34	-	5.50	-

Competitive Comparison of Tryptamine Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Tryptamine Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tryptamine Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tryptamine Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Tryptamine Therapeutics's EV-to-Revenue falls into.

Tryptamine Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Tryptamine Therapeutics's EV-to-Revenue for today is calculated as:

Tryptamine Therapeutics's current Enterprise Value is A$4.72 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Tryptamine Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.26 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics  (ASX:TYP) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Tryptamine Therapeutics's PS Ratiofor today is calculated as:

Tryptamine Therapeutics's share price for today is A$0.0275.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tryptamine Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description